Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock ...

The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...

Key Takeaways A Chinese-developed GLP-1 drug is as effective as Ozempic or Zepbound, clinical trial saysEcnoglutide helped patients lose more than 15% of their body weightNearly 93% of clinical trial ...

Patients who took a GLP-1 drug fared better than those in a control group at keeping their blood glucose levels in a healthy ...

An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with ...

Novo Nordisk ends partnership with Hims & Hers over compounded Wegovy, shaking the market. See why I recommend a wait-and-see ...

A GLP-1 medication used to treat type 2 diabetes and obesity may help cut a person's monthly migraine days by about half, a ...

GLP-1 therapies primarily use single-use injectable pens, contributing to medical waste challenges. The pharmaceutical ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...